

Solubility and Bioavailability Enhancement of Mosapride Citrate

*A thesis submitted in the partial fulfillment of the requirements for the
Master Degree in Pharmaceutical Sciences (Drug technology) by*

Mahmoud Abdelmonem Badawy

Bachelor of Pharmaceutical Sciences, 2006, Ain Shams University

*Research and development section head, Pharmed Healthcare for
pharmaceutical industries*

Under the supervision of

Prof. Dr. Omaima Ahmed Amin Sammour

*Professor and Head of Department of Pharmaceutics and Industrial
Pharmacy*

Faculty of Pharmacy, Ain Shams University

Dr. Amany Osama Kamel

*Associate Professor of Pharmaceutics and
Industrial Pharmacy,*

Faculty of Pharmacy, Ain Shams University

Ain Shams University

Faculty of Pharmacy

Department of Pharmaceutics and Industrial Pharmacy 2014

Acknowledgment

First of any acknowledgment goes to God (Allah) for his innumerable blessings and his guidance for me to the right path.

I would like to express my deepest appreciation and sincere gratitude to *Professor Dr. Omaima Ahmed Amin Sammour*, Professor and Head of Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, for her instructive supervision, kind help and generous attitude throughout the development of this work.

I offer my sincerest gratitude to *Dr. Amany Osama Kamel*, Associate Professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, who has supported me throughout my thesis with her patience and knowledge and provided me extensive personal and professional guidance and taught me a great deal about both scientific research and life in general. One simply could not wish for a better or friendlier supervisor.

I would especially like to thank *Dr. Hussein ElSawalhy*, R&D consultant at EGPI, who made me understand pharmaceutics and biopharmaceutics and taught me more than I could ever give his credit for him.

I also like to thank all my colleagues in Egyptian Group for Pharmaceutical industries (EGPI) and Pharmed Healthcare for pharmaceutical industries for their valuable help, support and encouragement.

Finally I would like to express my deepest thanks to my parents and my dear wife for their patience throughout the whole work carried out in this thesis.

List of Contents

Item	Page
List of Abbreviations	VII
List of Tables	IX
List of Figures	XIII
Abstract	XX
General Introduction	1
Scope of work	15
<i>Chapter I: Preparation of mosapride citrate tablets using liquisolid technique</i>	
Introduction	16
Experimental	24
Methodology	27
Determination of λ_{\max} of MC in distilled water, 0.1N HCl, acetate buffer pH 5 and simulated intestinal fluid	27
Construction of the calibration curve of MC in distilled water, 0.1N HCl, acetate buffer pH 5 and simulated intestinal fluid	27
Preformulation study	27
Solubility studies	29
Experimental design	29
Preparation of MC liquisolid systems	31
Evaluation of the flow properties of the prepared liquisolid systems	33
Compression of the prepared liquisolid systems into tablets	34

Item	Page
Evaluation of the prepared MC liquisolid tablets	35
Stability study	39
Data analysis	40
Results and Discussion	41
Determination of λ_{\max} of MC	41
Calibration curve of MC in distilled water, 0.1N HCl, acetate buffer pH 5 and simulated intestinal fluid	43
Preformulation study	48
Physical appearance	48
Differential Scanning Calorimetry (DSC)	48
X-ray diffraction	51
Infra red (IR) absorption spectroscopy	56
Solubility studies	58
Evaluation of the flow properties of the prepared liquisolid systems	59
Evaluation of the prepared MC liquisolid tablets	60
Physical appearance	60
Uniformity of content and weight	61
Tablet friability	61
Tablet crushing strength (hardness)	61
Tablet disintegration time	62
Dissolution studies	64
Differential scanning calorimetry (DSC)	95
X-ray diffraction (XRD)	96

Item	Page
Stability study	99
Conclusions	102
<i>Chapter II: Preparation of mosapride citrate tablets using complexation technique</i>	
Introduction	104
Experimental	119
Methodology	121
Construction of standard calibration curve of MC in phosphate buffer of Ph 6.8	121
Phase solubility studies	121
Experimental design	122
Preparation of MC-CD inclusion systems	124
Physicochemical characterization of MC-CD inclusion systems	125
In-vitro dissolution studies	125
Preparation of MC-CD inclusion complexes tablets	126
Evaluation of the prepared MC-CD inclusion complexes tablets	127
Stability study	127
Data analysis	128
Results and Discussion	129
Calibration curve of MC in phosphate buffer pH 6.8	129
Phase solubility studies	130
Physicochemical characterization of MC-CD inclusion systems	136

Item	Page
Differential scanning calorimetry studies	136
X-ray diffraction studies	141
Forier transform Infra- red analysis	146
In-vitro dissolution studies	152
Evaluation of the prepared MC-CD (CX-15) inclusion complexes tablets	180
Stability study	185
Conclusions	188
<i>Chapter III: Bioavailability and pharmacokinetic study of mosapride citrate tablets in healthy human volunteers</i>	
Introduction	190
Experimental	192
Methodology	194
LC-MS/MS assay of MC in human plasma	194
Pharmacokinetic study in healthy volunteers	196
Results and Discussion	200
Conclusions	215
Summery	216
References	220
Ethical committee	
Publications	
الملخص العربي	

List of Abbreviations

APT	Active pharmaceutical ingredient
ASD	Amorphous solid dispersion
ANOVA	Analysis of variance
AUC	Area under the curve
BCS	Biopharmaceutical classification system
BP	British pharmacopeia
CD	Cyclodextrin
CE	Complexation Efficiency
CI%	Carr's index
DSC	Differential scanning calorimetry
DR	Dissolution rate
FaSSIF	Fasted State Simulated Intestinal Fluid
FDA	Food and drug administration
FeSSIF	Fed state simulated intestinal fluid
FTIR	Fourier transform Infra red
GERD	Gastro-oesophageal reflux disease
GI	Gastro intestinal
GIT	Gastro intestinal tract
HP- β -CD	Hydroxypropyl betacyclodextrin
HR	Hausner's ratio
IR	Immediate release

IR	Infrared
IS	internal standard
D.C	Direct compression
Lf	Load factor
L-HPC21	Low substituted hydroxyl propyl cellulose
M- β -CD	Methyl β -cyclodextrin
MC	Mosapride citrate
MRT	Mean residence time
MTBE	Methyl-t-butyl-ether
PEG	Poly ethylene glycol
PVP	Polyvinyl pyrrolidone
SD	Standard deviation
SGF	Simulated gastric fluid
USP	United states pharmacopeia
UV	Ultra violet
XRD	X-ray diffractometry

List of Tables

Table no.	Table Name	Page
1	Factors and levels used in the factorial design	30
2	Formulae of different liquisolid systems used in the factorial design	31
3	Formulation characteristics of the prepared liquisolid systems	32
4	Relation between concentration of MC and absorbance at 271 nm in distilled water	44
5	Relation between concentration of MC and absorbance at 291 nm in 0.1 N HCl pH 1.2 applying second order derivative	45
6	Relation between concentration of MC and absorbance at 291 nm in acetate buffer pH 5 applying second order derivative	46
7	Relation between concentration of MC and absorbance at 291 nm in simulated intestinal fluid pH 6.5 applying second order derivative	47
8	Equilibrium solubility of MC in different solvents at 25°C	58
9	Flowability results of different liquisolid systems	60
10	Results of quality control tests of the liquisolid tablets	63
11	Dissolution results of liquisolid tablets prepared using Avicel PH102, pure drug and marketed tablets in 500 ml 0.1N HCl	66

Table no.	Table Name	Page
12	Dissolution results of liquisolid tablets prepared using Mannitol , pure drug and marketed tablets in 500 ml 0.1 N HCl	68
13	Dissolution results of liquisolid tablets prepared using Lactose D.C, pure drug and marketed tablets in 500 ml 0.1 N HCl	70
14	Dissolution results of LS-2, LS-4 and marketed tablets in 500 ml and 300 ml 0.1N HCl	80
15	Dissolution results of LS-2, LS-4, and market tablets in 500 ml 0.1 N HCl and acetate buffer	84
16	Transfer model results of LS-4, pure drug & marketed tablets using fasted state biorelevant media	91
17	Transfer model results of LS-4, pure drug & marketed tablets using fed state biorelevant media	93
18	Dissolution results of fresh and aged MC tablets LS-4 in 0.1 N HCl	100
19	Factors and levels used in the factorial design	123
20	Formulae of different inclusion systems used in the factorial design	123
21	Quantitative formulation of selected inclusion complex in a tablet dosage form	127
22	Relation between concentration of MC and absorbance at 291 nm in phosphate buffer pH 6.8 applying second order derivative	129
23	Data of phase solubility diagrams of MC with different CDs	134

Table no.	Table Name	Page
24	Percentage of MC dissolved from MC- β -CD systems in 500 ml 0.1N HCl	156
25	Percentage of MC dissolved from MC-HP- β -CD systems in 500 ml 0.1N HCl	158
26	Percentage of MC dissolved from MC-M- β -CD system in 500 ml 0.1N HCl	160
27	Percentage of MC dissolved from MC- β -CD systems in phosphate buffer pH6.8	166
28	Percentage of MC dissolved from MC-HP- β -CD systems in phosphate buffer of pH 6.8	168
29	Percentage of MC dissolved from MC-M- β -CD systems in phosphate buffer of pH 6.8	170
30	Percentage of MC dissolved from the optimum MC complexes in 300 ml 0.1N HCl	175
31	Transfer model results of optimum formulae, pure drug & marketed tablets using fasted state biorelevant media	178
32	Evaluation results of tablets prepared from CX-15 formulae	182
33	Dissolution of compressed tablet of mosapride-cyclodextrin inclusion complex	183
34	Dissolution results of aged CX-15 tablets	186
35	Relation between MC concentration and the peak area ratio of MC/IS in spiked human plasma	202
36	Recovery data of MC from spiked human plasma	204

Table no.	Table Name	Page
37	Within-day precision of the LC-MS/MS method for MC determination in human plasma	205
38	Inter-day precision and linearity of the LC-MS/MS method for ACV determination in human plasma	206
39	Mean plasma concentrations time data of MC from different formulae after oral administration	208
40	Pharmacokinetic parameters of MC after oral administration of different formulae	211

List of Figures

Figure no.	Figure Name	Page
1	Biopharmaceutics classification system (BCS) and viable formulation options based on the BCS	4
2	Schematic presentation for preparation of liquisolid systems	22
3	Experimental set-up of Transfer model	38
4	Ultraviolet-spectrum of MC in distilled water	41
5	Ultraviolet-spectrum of MC a) before and b) after applying second derivative in 0.1 N HCl pH 1.2	42
6	UltraViolet-spectrum of MC a) before and b) after applying second derivative in acetate buffer pH 5	42
7	UltraViolet-spectrum of MC a) before and b) after applying second derivative in simulated intestinal fluid pH 6.8	43
8	Calibration curve of MC in distilled water at 271 nm	45
9	Calibration curve of MC in 0.1 N HCl pH 1.2 at 291 nm applying second order derivative	46
10	Calibration curve of MC in acetate buffer pH 5 at 291 nm applying second order derivative	47
11	Calibration curve of MC in simulated intestinal fluid pH 6.8 at 291 nm applying second order derivative	48

Figure no.	Figure Name	Page
12	DSC thermograms of (A) MC (B) Avicel PH 102 (C) MC : Avicel PH 102 1:1 physical mixture (D) Mannitol (E) MC : Mannitol 1:1 physical mixture (F) Lactose D.C (G) MC : Lactose D.C 1:1 physical mixture (H) Aerosil 200 (I) MC : Aerosil 200 1:1 physical mixture	50
13	X-Ray diffraction pattern of (A) MC (B) Avicel PH102 (C) MC: Avicel 1:1 Physical mixture	52
14	X-Ray diffraction pattern of (A) MC (B) Mannitol (B) (C) MC: Mannitol 1:1 Physical mixture	53
15	X-Ray diffraction pattern of (A) MC (B) Lactose D.C (C) MC: Lactose D.C 1:1 Physical mixture	54
16	X-Ray diffraction pattern of (A) MC (B) Aerosil 200 (C) MC: Aerosil 200 1:1 Physical mixture	55
17	Infrared spectra of: (A)MC (B) Avicel PH 102 (C) MC : Avicel PH 102 1:1 physical mixture (D) Mannitol (E) MC : Mannitol 1:1 physical mixture (F) Lactose D.C (G) MC : Lactose D.C 1:1 physical mixture (H) Aerosil 200 (I) MC : Aerosil 200 1:1 physical mixture	57
18	Dissolution profiles of liquisolid tablets prepared using Avicel PH102, pure drug and marketed tablets in 500 ml 0.1 N HCl	67
19	Dissolution profiles of liquisolid tablets prepared using Mannitol, pure drug and marketed tablets in 500 ml 0.1 N HCl	69